Sodium–glucose co-transporter 2 inhibitors have revolutionized the management of chronic kidney disease. However, long-term data regarding their use are lacking. The post-trial follow-up study to EMPA-KIDNEY provides several insights into how the effects of these powerful medications might be optimized, but several key questions remain unanswered.

中文翻译：

---

EMPA-KIDNEY 的长期经验教训


钠-葡萄糖协同转运蛋白 2 抑制剂彻底改变了慢性肾病的管理。然而，缺乏关于其使用的长期数据。EMPA-KIDNEY 的试验后随访研究为如何优化这些强效药物的效果提供了一些见解，但几个关键问题仍未得到解答。